Dengue vaccine development: challenges and prospects

Wilder‐Smith, Annelies

doi:10.1097/qco.0000000000000871

Cited by 16 publications

(18 citation statements)

References 74 publications

(89 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although these findings are positive it is important to consider that there will be no one solution to controlling dengue and it remains vital to consider/evaluate other interventions (such as new vaccines as they become available [39]).…”

Section: Discussionmentioning

confidence: 99%

An economic evaluation ofWolbachiadeployments for dengue control in Vietnam

Turner

Quyen²,

Dias

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Dengue is a major public health challenge and a growing problem due to climate change. The release of Aedes aegypti mosquitoes infected with the intracellular bacterium Wolbachia is a novel form of vector control against dengue. However, there remains a need to evaluate the benefits of such an intervention at a large scale. In this paper, we evaluate the potential economic impact and cost-effectiveness of scaled Wolbachia deployments as a form of dengue control in Vietnam - targeted at the highest burden urban areas. Methods Ten settings within Vietnam were identified as priority locations for potential future Wolbachia deployments (using a population replacement strategy). The effectiveness of Wolbachia deployments in reducing the incidence of symptomatic dengue cases was assumed to be 75%. We assumed that the intervention would maintain this effectiveness for at least 20 years (but tested this assumption in the sensitivity analysis). A cost-utility analysis and cost-benefit analysis were conducted. Results From the health sector perspective, the Wolbachia intervention was projected to cost US$420 per disability-adjusted life year (DALY) averted. From the societal perspective, the overall cost-effectiveness ratio was negative, i.e. the economic benefits outweighed the costs. These results are contingent on the long-term effectiveness of Wolbachia releases being sustained for 20 years. However, the intervention was still classed as cost-effective across the majority of the settings when assuming only 10 years of benefits. Conclusion Overall, we found that targeting high burden cities with Wolbachia deployments would be a cost-effective intervention in Vietnam and generate notable broader benefits besides health gains.

show abstract

Section: Discussionmentioning

confidence: 99%

An economic evaluation ofWolbachiadeployments for dengue control in Vietnam

Turner

Quyen²,

Dias

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…A licensed CHIKV vaccine is expected to be released soon [35] . Currently, two licensed vaccines for DENV are available, and others have been tested in clinical trials [36] . It's noteworthy to mention that the determination of DENV pre-exposure (by IgG antibodies) has been considered relevant in the context of dengue vaccine Dengvaxia® since there is evidence of an excess risk of severe dengue in IgG seronegative vaccine recipients [ 37 , 38 ].…”

Section: Discussionmentioning

confidence: 99%

High seroprevalence of antibodies against arboviruses in postpartum women in Salvador, Brazil

Bastos Filho,

Francisco,

Santos

et al. 2023

IJID Regions

View full text Add to dashboard Cite

“…Therefore, any dengue vaccine needs to induce a balanced response against all four dengue serotypes, in case of Dengvaxia by mixing of four live vectors. Dengvaxia has shown to provide good protection against dengue haemorrhagic fever in seropositive populations and is now recommended for use in naturally primed individuals as a kind of booster vaccine [159,160].…”

Section: Box 2 -Multiple Approaches To Construct Recombinant Live-att...mentioning

confidence: 99%

YF17D‐based vaccines – standing on the shoulders of a giant

Sanchez‐Felipe,

Alpizar,

et al. 2024

Eur J Immunol

View full text Add to dashboard Cite

SummaryLive‐attenuated yellow fever vaccine (YF17D) was developed in the 1930s as the first ever empirically derived human vaccine. Ninety years later, it is still a benchmark for vaccines made today. YF17D triggers a particularly broad and polyfunctional response engaging multiple arms of innate, humoral and cellular immunity. This unique immunogenicity translates into an extraordinary vaccine efficacy and outstanding longevity of protection, possibly by single‐dose immunization. More recently, progress in molecular virology and synthetic biology allowed engineering of YF17D as a powerful vector and promising platform for the development of novel recombinant live vaccines, including two licensed vaccines against Japanese encephalitis and dengue, even in paediatric use. Likewise, numerous chimeric and transgenic preclinical candidates have been described. These include prophylactic vaccines against emerging viral infections (e.g. Lassa, Zika and SARS‐CoV‐2) and parasitic diseases (e.g. malaria), as well as therapeutic applications targeting persistent infections (e.g. HIV and chronic hepatitis), and cancer. Efforts to overcome historical safety concerns and manufacturing challenges are ongoing and pave the way for wider use of YF17D‐based vaccines. In this review, we summarize recent insights regarding YF17D as vaccine platform, and how YF17D‐based vaccines may complement as well as differentiate from other emerging modalities in response to unmet medical needs and for pandemic preparedness.

show abstract

Dengue vaccine development: challenges and prospects

Cited by 16 publications

References 74 publications

An economic evaluation ofWolbachiadeployments for dengue control in Vietnam

An economic evaluation ofWolbachiadeployments for dengue control in Vietnam

High seroprevalence of antibodies against arboviruses in postpartum women in Salvador, Brazil

YF17D‐based vaccines – standing on the shoulders of a giant

Contact Info

Product

Resources

About